A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose In Patients With Leukemia Or Myelodysplastic Syndromes

Trial Profile

A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose In Patients With Leukemia Or Myelodysplastic Syndromes

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2015

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors MethylGene
  • Most Recent Events

    • 12 May 2009 Additional lead trial investigator (Martell R) identified as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Status changed from suspended to completed, according to clinicaltrials.gov.
    • 22 Sep 2008 Celgene reported as a trial affiliate and sponsor by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top